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Abstract
Introduction: Primary germ cell tumours with mediastinal location comprise 1–6% of mediastinal tumours and 2–5% of all germ 
cell tumours occurring in adults. They are identified mostly in the 3rd decade of life, in 90% of cases in men. The most common 
symptoms are dyspnea, chest pain, cough, fever and weight loss.
The aim of the present study was the analysis of our own results of treatment of primary germ cell tumours with mediastinal 
location, and a review of the literature concerning this subject.
Material and methods: Five patients (4 males, 1 female) median age 27.8 years (range 23–30 years) treated in the period from 
1999 to 2009 in Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Lung Cancer and Chest 
Tumours in Warsaw, due to germinal tumours with primary mediastinal location, entered the study. 
Results: All patients received chemotherapy according to the BEP regimen. All patients achieved an objective response to treat-
ment. Two patients died due to disease progression in spite of II- and III-line treatment. Three patients are still in follow-up. The 
median survival time was 55.8 months (range 8.0–120.0 months).
Conclusions: Primary mediastinal germ cell tumours have worse prognosis than do those with gonadal location. Based on our 
observations and review of the literature, it can be concluded that the results of treatment of non-seminoma type germ cell 
tumours with primary mediastinal location remain poor. Patients who develop early recurrence or progression during first-line 
chemotherapy are particularly at risk of unfavourable outcome. Identification of new standards of treatment in tumours resistant 
to cisplatin require further studies evaluating the effectiveness of new generation cytostatic drugs.
Key words: germ cell tumours, mediastinum, chemotherapy, radiotherapy
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Streszczenie
Wstęp: Pierwotne nowotwory z komórek rozrodczych o lokalizacji śródpiersiowej stanowią 1–6% guzów śródpiersia oraz 2–5% 
wszystkich nowotworów z komórek rozrodczych występujących u dorosłych. Rozpoznawane są najczęściej w 3. dekadzie życia, 
w 90% u mężczyzn. Najczęstsze objawy to: duszność, bóle w klatce piersiowej, kaszel, stany podgorączkowe i utrata masy ciała. 
Celem pracy była ocena wyników leczenia pierwotnych nowotworów z komórek rozrodczych o lokalizacji śródpiersiowej i przegląd 
piśmiennictwa poświęconego tej tematyce.
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Materiał i metody: W okresie od 1999 do 2009 roku w Klinice Nowotworów Płuca i Klatki Piersiowej Centrum Onkologii-Instytut 
im. Marii Skłodowskiej-Curie w Warszawie leczono 5 chorych z nowotworem z komórek rozrodczych o pierwotnej lokalizacji 
śródpiersiowej, 4 mężczyzn i 1 kobietę. Średnia wieku wyniosła 27,8 roku (zakres 23–30).
Wyniki: U wszystkich chorych zastosowano chemioterapię według schematu BEP. U wszystkich chorych uzyskano obiektywną 
odpowiedź na leczenie. Dwóch chorych zmarło z powodu progresji choroby pomimo stosowania chemioterapii II i III linii. Trzech 
chorych nadal pozostaje w obserwacji. Mediana czasu przeżycia wyniosła 55,8 miesiąca (zakres 8,0–120,0).
Wnioski: Pierwotne nowotwory z komórek rozrodczych o lokalizacji śródpiersiowej są nowotworami o rokowaniu gorszym niż 
w lokalizacji gonadalnej. Na podstawie obserwacji własnych i przeglądu piśmiennictwa można stwierdzić, że wyniki leczenia pierwot-
nych nienasieniaków w lokalizacji śródpiersiowej pozostają niezadowalające. Szczególnie niekorzystne są wyniki leczenia chorych, 
u których dochodzi do wczesnej wznowy lub progresji w trakcie chemioterapii I linii. Określenie nowych standardów postępowania 
w nowotworach opornych na cisplatynę wymaga dalszych badań oceniających skuteczność cytostatyków nowych generacji.
Słowa kluczowe: nowotwory z komórek rozrodczych, śródpiersie, chemioterapia, radioterapia
Pneumonol. Alergol. Pol. 2014; 82: 116–124 
Introduction
Primary germ cell tumours with mediasti-
nal location constitute 1–6% of tumours of the 
mediastinum, and approximately 2–5% of all 
germ cell tumours in adults. They are the most 
frequent extragonadal tumours [1, 2]. The second 
extragonadal location in respect of prevalence 
is the retroperitoneal area; other extremely rare 
locations include the hypophysis, pineal body, 
liver and lung [2]. Germ cell neoplasms are 
usually diagnosed in the third decade of life, 
in 90% of cases in men [3]. Tumours located in 
the mediastinum are usually symptomatic. The 
most frequent symptoms are dyspnea, chest pain, 
cough, low grade fever and weight loss [4]. The 
most important diagnostic procedures are: com-
puted tomography of the chest (chest CT) and 
determination of serum tumour markers concen-
tration — the b subunit of human chorionic go-
nadotropin (bHCG) and alpha-fetoprotein (AFP). 
Prior to treatment, attempts should be made to 
identify the histopathological type of tumour. The 
material for diagnosis is obtained with the help of 
invasive methods, such as transbronchial biopsy 
and, rarely, mediastinoscopy or thoracotomy. 
Taking into account their morphology, germ 
cell tumours are divided into two groups: sem-
inomas and nonseminomas. Nonseminomas 
are heterogeneous neoplasms; they include 
teratoma maturum and teratoma immaturum, 
yolk sac tumour (YST) also known as endoder-
mal sinus tumour (EST), embryonal carcinoma, 
chorioncarcinoma and mixed germ cell tumours 
(MGCT) [5]. In the case of nonseminomas, ele-
vated bHCG serum level is found in 30–50% of 
patients, whereas AFP — in 60–80% of patients 
[3]. In the case of seminomas, only bHCG serum 
level is elevated. 
According to the International Germ Cell 
Cancer Cooperative Group (IGCCCG), based 
on histopathological diagnosis, serum tumour 
markers level, location of primary lesion and the 
presence and location of metastases, patients are 
classified into one out of three prognostic groups. 
In the case of seminoma, the patient is classified 
into either the group with good or with medium 
prognosis. In the case of mediastinal non-sem-
inoma, the patient is classified into the group 
with poor prognosis, irrespective of the levels 
of tumour markers [6]. Therapeutic procedures 
in the treatment of nonseminomas include cis-
platin-based chemotherapy, and in the case of 
lack of complete remission — surgical removal 
of residual lesions.
The objective of the study
The objective of the study was to analyse the 
results of treatment in primary germ cell tumours 
with mediastinal location in patients treated in 
the Lung Cancer and Chest Tumours Department, 
Maria Sklodowska-Curie Memorial Cancer Centre 
and Institute of Oncology in Warsaw. Our own 
results were compared with the literature con-
cerning this subject.
Material and methods
During the period from 1999 until 2009, at 
the Lung Cancer and Chest Tumours Department, 
Maria Sklodowska-Curie Memorial Cancer Centre 
and Institute of Oncology in Warsaw, five patients 
(4 men and 1 woman), mean age 27.8 years (range 
23–30 years), with germ cell tumour with primary 
location in the mediastinum, were treated.
Four patients were diagnosed with pure 
endodermal sinus tumour — EST (Fig. 1); in 
one case MGCT (EST, embryonal carcinoma and 
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Table 1. Patients’ clinical characteristics
Tabela 1. Charakterystyka kliniczna chorych
Patient Sex Age Diagnosis KPS AFP
(IU/mL)
AFP level
bHCG
(mIU/mL)
bHCG level
Surgical  
treatment
1 M 30 EST 100 20318 0.1 YES
RX
2 M 28 EST 100 20209 0.1 YES
R1
3 K 29 EST 80 58390 0.9 NO
4 M 29 EST 100 469 0.1 YES
R0
5 M 23 EST + carcinoma embryonale 
+ teratoma maturum
80 1217 42028 NO
EST — Endodermal Sinus Tumour; KPS — Karnofsky’s Performance Status; AFP — a-fetoprotein; bHCG — the b subunit of human chorionic gonadotropin
Figure 1. Endodermal sinus tumour (EST) with mediastinal location
Rycina 1. Fragment utkania endodermal sinus tumour (EST) o lokali-
zacji śródpiersiowej
Figure 2. Mixed germ cell tumor with mediastinal location (teratoma 
and embryonal carcinoma)
Rycina 2. Mixed germ cell tumor. Wycinek z guza śródpiersia. Widocz-
ne są fragmenty utkania teratoma i embryonal carcinoma
teratoma) was diagnosed (Fig. 2). In all of them, 
significantly elevated AFP concentration (range 
469 — 58390 IU/mL) was found. Elevated bHCG 
was noted in one patient only (MGCT). According 
to Karnofsky’s scale, all patients had good or 
very good performance status. All patients were 
diagnosed using spiral chest CT and/or magnetic 
resonance and surgical biopsy. Gonadal location 
of neoplasm was excluded in all of them. Due to 
primary mediastinal location of germ cell tumour, 
all patients were classified into the group with 
poor prognosis.
The clinical characteristics of the study group 
are presented in Table 1.
Results
The patients received chemotherapy, com-
bined with surgical treatment in some of them. 
The summary of therapeutic methods was includ-
ed in Table 2. All patients achieved an objective 
response to treatment. Two patients died due to 
disease progression, and three patients are still 
in follow up. The median survival time was 55.8 
months (range 8.0–120.0).
Due to the small number of patients, a brief 
description of the treatment used in individual 
subjects has been presented below.
The first patient underwent operation on 8th 
February, 2008 — resection of tumour (type RX). 
Diagnosis of EST was made. Since March, 2008, 
the patient has received 6 cycles of BEP regimen 
(bleomycin, etoposide, cisplatin). Complete re-
sponse (CR) was achieved (Figs 3, 4). The patient 
received second look surgery on 18th of June, 2008. 
No living cancer cells were found. In September, 
2008, disease progression (PD) was found (elevat-
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Table 2. Treatment and response rate
Tabela 2. Leczenie i uzyskane odpowiedzi
Pa-
tient
Treatment n Treatment 
response
Reope-
ration
Pathological 
response
Progression 
free survival 
(months)
Second line 
of chemo-
therapy
Third line  
of chemo-
therapy
Radio-
therapy
OS
(months)
1 BEP 6 CR Yes CR 3 VBL+I-
FO+DDP
OXL+PXL+-
GCB
Yes 19
2 BEP 4 CR Yes CR – – – No 60
3 BEP 6 CR Yes CR 3 VeIP – Yes 120
4 BEP 4 PR Yes CR – – – No 72
5 BEP 3 PD No – 2 TIP – Yes 8
BEP — bleomycin, etoposide, cisplatin; VBL — vinblastine; IFO — ifosfamide; DDP — cisplatin; VeIP — etoposide, ifosfamide, cisplatin; TIP — paclitaxel, ifosfamide, 
cisplatin; OXL — oxaliplatin; GCB — gemcitabine; PXL — paclitaxel; RTH — radiotherapy; CTH — chemotherapy
ed AFP and recurrence in the chest). The patient 
was qualified to second-line treatment according 
to the following regimen: vinblastine 8.25 mg 
i.v./m2 + ifosfamide 2400 mg i.v./m2 + cisplatin 
40 mg i.v./m2. Treatment was discontinued after 
administration of two cycles in November, 2008, 
Figure 3. Chest CT with contrast before chemotherapy (mediastinal 
neoplasia with pleural infiltration — marked with arrows)
Rycina 3. KT KLP z kontrastem przed chemioterapią (masy nowotwo-
rowe w śródpiersiu oraz guzowaty naciek opłucnej — strzałki)
Figure 4. Chest CT with contrast after chemotherapy (complete 
regression)
Rycina 4. KT KLP po chemioterapii (całkowita regresja zmian)
due to PD. Subsequently, the patient was qualified 
to rescue chemotherapy (CHT) based on oxalipla-
tin, paclitaxel and gemcitabine. After 4 cycles of 
CHT, in March, 2009, treatment was stopped due 
to PD. Palliative irradiation to the mediastinal 
area (20 Gy/4Gy) was performed. In September, 
2009, further progression was found. The patient 
received symptomatic treatment only and died in 
November, 2009.
The second patient underwent surgery in 
January, 2008 — right-sided thoracotomy with 
removal of tumour, and medial lobectomy (type 
R1). Diagnosis of EST was made. In February, 
2008, significantly elevated AFP was noted (20209 
IU/mL). Chest CT revealed disease progression. 
In March, 2008, the patient started chemotherapy 
with BEP regimen. The treatment was complicat-
ed by neutropenic fever requiring hospitalisation. 
Four cycles of BEP were given, each of which was 
complicated with neutropenia and thrombocy-
topenia. In June, 2008, the patient underwent 
second look surgery — no living cancer cells were 
found. The patient is in still follow-up, with no 
features of active neoplastic disease.
The third patient, female, underwent medi-
astinoscopy in January, 1999. She was diagnosed 
EST. In February, 1999, due to disease progression 
in the mediastinum and lungs, and elevated AFP 
(58 390 IU/mL), the patient began chemotherapy 
according to the BEP regimen. Six cycles were 
given with radiological partial response (PR) and 
normalisation of tumour markers. No clinically 
significant haematological and non-haematologi-
cal complications were observed. In August, 1999, 
thoracotomy was performed, residual lesions 
in the mediastinum were removed and bypass 
of the superior vena cava was performed. The 
pathological examination revealed only features 
of necrosis; no neoplastic cells were found. Four 
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weeks after the operation, AFP concentration in-
creased to 220 IU/mL with no signs of radiological 
PD. Second-line treatment according to the VeIP 
regimen (etoposide, ifosfamide, cisplatin) was 
started. On the second day of chemotherapy, the 
condition of the patient deteriorated. Right-sided 
hemiparesis occurred. Computed tomography of 
the brain revealed the presence of two metastat-
ic sites. The patient received palliative whole 
brain radiation (30 Gy/10 fr.). Due to complete 
remission in the chest confirmed by 99mTcMI-
BI scintigraphy, and normalisation of tumour 
marker levels, the patient was qualified to brain 
radio-surgical treatment. A 13 Gy single dose was 
given, using rotary technique with 5 arches and 
1 isocentre. The treatment was ended in March, 
2000. The patient is in still follow-up; she is in 
a good performance status with no biochemical 
or radiological features of PD. 
The fourth patient underwent surgery on 
12th June, 2008 — left-sided thoracotomy with 
removal of tumour mass. Pathological diagnosis 
was EST. Due to elevated AFP (469 IU), CT was 
performed, which showed local recurrence with 
no distant metastases. Four cycles of chemother-
apy according to the BEP regimen were given, ra-
diological PR was achieved and normalisation of 
the markers levels were obtained. No significant 
haematological or non-haematological toxicity of 
treatment was observed. The patient underwent 
second look surgery — no neoplastic cells were 
found, only areas of fibrosis and hyalinisation 
with foci of necrosis. The patient is still in follow- 
-up; he is in a very good health condition with 
no signs of active disease. 
The last patient had mediastinoscopy per-
formed in 2008; MGCT (carcinoma embryonale 
with elements of EST and fields of teratoma 
maturum) was diagnosed. Radiological examina-
tion of the chest revealed numerous metastatic 
lesions. AFP concentration was 1217.8 mIU/
mL and bHCG was 42028 mIU/mL. The patient 
was qualified to chemotherapy according to the 
BEP regimen. Treatment was complicated with 
anaemia grade 2 requiring a red blood cells con-
centrate transfusion, and neutropenia grade 4 
with no signs of neutropenic fever (G-CSF was 
administered as a prophylaxis). After two cycles 
of chemotherapy, a decrease in the level of the 
markers (AFP — 30.8 mIU/mL; bHCG — 784.2 
mIU/mL) and radiological regression of the le-
sion in the mediastinum was achieved. After 
the third cycle of BEP chemotherapy, the bHCG 
level increased to 930 mIU/mL (with no radio-
logical signs local PD). The patient was qualified 
to second-line treatment according to the TIP 
(paclitaxel, ifosfamide, cisplatin) regimen. Four 
cycles of second-line chemotherapy were given. 
A slow decrease of bHCG concentration was 
observed. When chemotherapy was completed 
in July, 2009, neurological symptoms occurred 
(left-sided hemiparesis, disequilibrium), so brain 
CT was performed showing multiple metastatic 
lesions in the brain and cerebellum. The patient 
received palliative whole brain radiation (20 Gy/5 
fr.). A slight improvement in general health status 
was achieved, but the patient died 4 weeks later.
Discussion
Current recommendations concerning treat-
ment of patients with primary nonseminomatous 
germ cell tumours of the mediastinum suggest 
a multidisciplinary approach [7]. Due to the loca-
tion of such tumours, the patients are classified 
into the group with poor prognosis (according to 
the IGCCCG). It is recommended to give 4 cycles 
of chemotherapy according to the BEP regimen, 
and then, if the level of the markers is decreased 
(examination 4 weeks after the last chemothera-
py), the patient is qualified to thoracotomy in or-
der to remove residual lesions. In the case of lack 
of complete regression, and when an objective 
response was achieved, it is possible to continue 
chemotherapy for up to 6 cycles. In the case of 
progression during treatment or recurrence of the 
disease, it is recommended to start second-line 
chemotherapy.
We have presented our own results and a 
review of the literature concerning the strategy of 
a therapeutical approach and prognostic factors in 
patients with diagnosed primary nonseminoma-
tous germ cell tumours with mediastinal location. 
Prognostic factors
In the published analysis of 635 patients 
with extragonadal location of germ cell tumours, 
primary nonseminomatous tumours of the medi-
astinum were diagnosed in 287 patients [8]. The 
aim of the analysis was to determine prognostic 
factors. The patients with seminomas had very 
good prognosis (89% of patients achieved five-
year survival). In the population of patients 
with diagnosed mediastinal nonseminoma, 65% 
and 45% of patients survived 2 and 5 years, 
respectively. Better prognosis was seen in the 
patients with retroperitoneal location (two- and 
five-year survival was achieved in 76% and 62% 
of patients, respectively). The tumour type was 
considered the most significant prognostic factor. 
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An additional analysis allowed four prognostic 
groups to be distinguished. Classification into the 
group depended on the obtained number of points. 
The evaluation concerned the presence of liver 
and lung metastases, elevated bHCG (1 point each) 
and the presence of mediastinal location and CNS 
metastases (2 points each). In the group of patients 
with nonseminomatous germ cell tumours, the best 
prognosis concerned the patients who received 0–1 
point, whereas the worst — those who received > 3 
points (five-year survival rates were 69% and 17%, 
respectively) [8]. It was thought that the factors 
that influence poor prognosis were mediastinal 
location and the presence of metastatic lesions at 
initial diagnosis, and the location of metastatic dis-
ease in the central nervous system was considered 
especially unfavourable [8]. 
The best prognosis concerned the patients 
> 29 years of age, without metastatic disease and 
without elevated levels of bHCG. The proportion 
of five-year survivals in this group was 84% [8]. 
Among the described patients treated at the 
Lung Cancer and Chest Tumours Department, 
two patients met the above-mentioned criteria. 
In both cases, standard chemotherapy allowed 
radiological partial response to be achieved with 
normalisation of the markers. After chemother-
apy, the patients underwent thoracotomy with 
removal of residual lesions in the mediastinum. 
Both patients are still in follow-up and in very 
good general health condition (currently 60 and 
120 months after diagnosis).
Surgical treatment
Surgical treatment constitutes an integral 
part of the therapy of patients with primary 
mediastinal germ cell tumours located in the 
mediastinum. In the case of normalisation of the 
level of the tumour marker concentrations after 
chemotherapy, in patients with no distant me-
tastases, it is recommended to remove residual 
lesions. Evaluation of postoperative specimens 
is crucial for prognosis. 
In patients with the presence of distant metasta-
ses, clear recommendations have not been made [7]. 
It is important to measure the level of the 
markers just before consecutive cycles of che-
motherapy, and 4 weeks after chemotherapy 
is completed. Such a policy allows for reliable 
judgement of the dynamics of the disease [6]. In 
the case of normalisation of tumour marker levels 
or persistently elevated values in two consecutive 
examinations made at the interval of 4 weeks, 
surgical treatment is recommended. If more than 
10% of “viable” neoplastic cells are found in surgi-
cal specimens, two cycles of supplementary che-
motherapy are applied [6]. The increase of tumour 
marker concentrations during chemotherapy or 
immediately after it is completed is an indication 
for second-line chemotherapy. 
The analysis of the results of treatment of 158 
patients with primary mediastinal non-seminomas 
was published [9]. The operation was performed 
4–5 weeks after the last cycle of chemotherapy 
(which allowed regeneration of bone marrow 
and evaluation of the level of the markers). The 
operation consisted in resection of residual le-
sions together with adjacent structures (usually 
infiltration concerned the pericardium — 74%, 
the lung — 55% and the phrenic nerve — 30%). In 
some cases it was necessary to carry out vascular 
reconstruction. Perioperative complications were 
seen in 23% of patients, including 6% of deaths. 
Histopathological examination of residual lesions 
usually showed the presence of necrosis and tera-
toma (60%), and in the remaining patients — per-
sistent germ cell tumours, sarcomas and cancers. 
In some cases, no correlation was found between 
the results of postoperative pathological exam-
ination and the levels of the markers (in 50% of 
patients with residual neoplastic tissue, the levels 
of AFP and bHCG before the operation were low). 
The best prognosis was seen in the patients 
in whom the postoperative specimen examination 
revealed only necrosis. The prognosis was 6 times 
worse for the patients who developed teratoma 
and 15 times worse for the patients with the 
malignant neoplasm [9]. An independent nega-
tive prognostic factor was elevated levels of the 
markers found after the operation. Similar results 
have been shown by Kesler and Sakurai [10, 11]. 
Neoplastic cells were not found in residual le-
sions in any of the patients of the Lung Cancer and 
Chest Tumours Department who underwent sur-
gery after first-line chemotherapy. Nevertheless, 
two patients developed a rapid recurrence of the 
disease (in one case — a massive local recurrence 
occurred 2 months after the operation, in the 
second case — metastases to the CNS occurred 
6 weeks after the surgery).
Surgical procedures are a separate issue in 
the treatment of mediastinal germ cell tumours. 
Tumour biopsy is recommended prior to treatment, 
to determine the histopathological type of the tu-
mour. It is not recommended to remove the whole 
lesion for diagnostic and therapeutic purposes be-
cause such a strategy deteriorates prognosis [10]. 
In the material from the Lung Cancer and 
Chest Tumours Department, in three cases, diag-
nosis was made based on evaluation of the whole 
Pneumonologia i Alergologia Polska 2014, tom 82, nr 2, strony 116–124 
122 www.pneumonologia.viamedica.pl
tumour removed during thoracotomy. The extent 
of the operation was influenced by a lack of preop-
erative diagnosis. In one case there were also some 
difficulties connected with obtaining a correct 
histopathological diagnosis – the initial diagnosis 
was thymoma. Immunohistochemical analysis 
and evaluation of the markers typical of germ cell 
tumours are very helpful for diagnosis [6].
Second-line treatment
Approximately 80% of patients with primary 
germ cell tumours located in the mediastinum 
benefit from first-line cisplatin-based chemother-
apy [12]. In the remaining patients, resistance to 
cisplatin (PD during 4 weeks after chemotherapy 
completion) or complete resistance to cisplatin 
(PD during treatment) is observed [13]. Life 
expectancy for patients in whom PD occurred 
during or shortly after cisplatin-based chemother-
apy is poor. It has been shown in the published 
analysis of treatment results of 164 patients 
with germ cell tumours (17% with mediastinal 
location) that independent negative prognostic 
factors were: time to progression < 2 years af-
ter chemotherapy completion, lack of CR, and 
high levels of the markers found at the moment 
of recurrence (AFP >100 mIU/mL, bHCG >100 
mIU/mL) [14]. Among the patients with three 
negative prognostic factors, only 7% survived for 
2 years. In second-line treatment, chemotherapy 
according to the VIP, TIP or VeIP regimens is 
used as a rule [7]. It allows objective response 
to be achieved in 30-40% of patients [6]. Due to 
the limited efficacy of cytostatic drugs applied 
to date, research is being conducted in order to 
determine the efficacy of other therapeutical 
options. Most publications have concerned oral 
forms of etoposide, paclitaxel, gemcitabine and 
oxaliplatin. In phase II studies, 20% of objective 
responses to treatment with gemcitabine were 
obtained in patients with recurrent or cispla-
tin-refractory primary mediastinal germ cell 
tumours [15, 16]. Similar results were obtained 
using monotherapy with oxaliplatin [17]. In 
a phase II study of 35 patients that evaluated 
the efficacy of a two-drug regimen (gemcitabine 
plus oxaliplatin), in second-line treatment, 46% 
of objective responses with the median survival 
of 13 months were achieved [18]. In a study that 
evaluated the efficacy of a three-drug regimen 
(paclitaxel, gemcitabine and oxaliplatin) in 
a group of 41 patients with recurrent germ cell 
tumour resistant to cisplatin, 51% of objective 
responses, including 15% of complete respons-
es, were achieved [19].
Another therapeutical strategy for patients 
with recurrent germ cell tumours may be high-
dose chemotherapy with autologous stem cell 
transplantation. Published initial results are 
encouraging in respect of treatment of patients 
with recurrence and patients with mediastinal 
non-seminomas, for whom this strategy was ap-
plied as a first-line treatment [13]. Unfortunately, 
despite the encouraging results of phase II stud-
ies, until now we do not have positive results of 
randomised clinical trials, which could change 
the standards of treatment. 
Among the patients treated at the Lung 
Cancer and Chest Tumours Department, progres-
sion of the disease after first-line chemotherapy 
occurred in two cases; in one case, progression 
in the form of elevated markers occurred during 
chemotherapy. Second-line therapy according to 
TIP and VeIP, and GOP regimens were used. No 
responses to second line treatment were observed.
Metastases to the central nervous system
The factor that significantly deteriorates 
prognosis for patients with germ cell tumours 
is the presence of metastases to the CNS. This 
problem concerns 2–3% of patients [20]. An 
analysis conducted on 198 patients allowed three 
prognostic groups to be distinguished [21]. The 
first group included patients with lesions in the 
CNS observed at the moment of diagnosis. The 
second group included patients with isolated 
recurrence in the CNS. The third group included 
patients with both systemic and CNS recurrence. 
The proportion of two-year survival for groups 1, 2 
and 3 was 57%, 44% and 22%, respectively. Clear 
recommendations concerning treatment of CNS 
metastases have not been made. However, it seems 
that chemotherapy followed by CNS radiothera-
py might improve prognosis [21]. In the above 
mentioned publication, combined treatment was 
used most frequently (129 patients out of 198). It 
consisted of chemotherapy with removal of resid-
ual lesions located outside the brain followed by 
radiotherapy and/or surgical treatment of lesions 
in the CNS. Independent negative prognostic fac-
tors were diagnosis of chorioncarcinoma, lack of 
combined treatment and the presence of multiple 
lesions in the CNS [21]. Combined treatment of 
patients with metastatic lesions in the CNS is the 
only chance to prolong survival. 
Due to the fact that sometimes patients after 
CNS radiotherapy have survived for many years, 
special attention should be paid to the risk of 
radiation-induced complications. Neurological 
disorders may occur months, and even years, 
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after completion of treatment [20]. They include 
a wide spectrum of symptoms: memory disorders, 
motor disorders including ataxia, and personality 
changes. There have also been cases of secondary 
neoplasms of the CNS induced by irradiation, 
and progressing, multifocal leukoencephalopathy, 
which was finally the cause of death [20].
In the materials from our department, among 
patients with primary mediastinal nonsemino-
mas, metastases to the CNS were found in two 
cases. In both patients, they became clinically 
evident during active treatment. One female pa-
tient received palliative radiation to the CNS, and 
then residual brain lesions were removed using 
radiosurgery. The patient has been in follow-up 
for 10 years, with no features of recurrence of the 
disease and with no late complications of applied 
treatment. The second patient received palliative 
radiation to the CNS; slight improvement in his 
general and neurological health was achieved, 
but he died 4 weeks afterwards, and the disease 
dissemination to the CNS has been considered as 
a direct reason for treatment failure. 
Observation after treatment
Patients who have completed treatment due 
to primary mediastinal germ cell tumour re-
quire intensive oncological supervision. It is 
recommended to determine systematically (every 
2 months during the first year, then every 4 months 
during the second year, and every 6 months during 
the successive years of observation) the level of 
the markers and to perform imaging examinations 
[7]. In patients with this type of tumour, recur-
rence of the disease may occur even many years 
after treatment. It is also important to take into 
account the risk of the occurrence of secondary 
neoplasms, among others metachronous testicular 
cancer (accumulated risk amounts to 10%, and 
it is higher in patients with primary nonsemino-
matous tumours with retroperitoneal location) 
[6]. A dependence between mediastinal germ cell 
tumours of nonseminomatous histology, and in-
creased frequency of haematological neoplasms, 
especially acute megakaryocytic leukaemia, and 
more rarely myelodysplasia, histiocytosis or 
mastocytosis, was described [22]. Chromosomal 
aberrations typical of primary mediastinal germ 
cell tumours (12p) were found in blasts, which 
presumes a common progenitor cell for the two 
proliferations [23]. Haematological proliferations 
occur usually during the 6 months after diagnosis 
of a germ cell tumour, and prognosis for this group 
is poor, with a predicted mean survival time of 
approximately 5 months [22]. 
Conclusions
Primary germ cell tumours of the mediasti-
num are neoplasms with worse prognosis than 
that for tumours with gonadal location. Patients 
with diagnosed primary mediastinal germ cell tu-
mours constitute a heterogenic group in respect of 
morphology of tumour, clinical course and prog-
nosis. This paper has presented patients treated at 
the Lung Cancer and Chest Tumours Department 
in Warsaw. The used combined treatment allowed 
complete remission of lesions to be achieved (also 
in a female patient with metastases to the lung, 
found at the moment of diagnosis, and metastases 
to the CNS that manifested themselves during sec-
ond-line chemotherapy). The surviving patients 
have been in follow-up for 11 years, 3 years and 
18 months from the moment of diagnosis of the 
disease. Two patients died due to progression of 
the disease, despite several lines (2 and 3) of ap-
plied chemotherapy. One patient died (22 months 
after diagnosis) due to progression of the disease 
in the chest, and another patient died (8 months 
after diagnosis) due to PD in the CNS.
Based on our own observations and a review 
of the literature, we conclude that the results 
of treatment of primary non-seminomas with 
mediastinal location remain unsatisfactory. The 
results of treatment of patients who developed 
early recurrence or progression during first-line 
chemotherapy are especially unfavourable. In 
order to determine new standards of treatment of 
cisplatin-resistant neoplasms, further research to 
evaluate the efficacy of new generation cytostatic 
drugs is required.
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